KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) EBITDA: 2015-2025

Historic EBITDA for BeOne Medicines (ONC) over the last 11 years, with Sep 2025 value amounting to $163.1 million.

  • BeOne Medicines' EBITDA rose 235.63% to $163.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $182.7 million, marking a year-over-year increase of 120.94%. This contributed to the annual value of -$568.2 million for FY2024, which is 52.95% up from last year.
  • According to the latest figures from Q3 2025, BeOne Medicines' EBITDA is $163.1 million, which was up 85.60% from $87.9 million recorded in Q2 2025.
  • BeOne Medicines' 5-year EBITDA high stood at $190.6 million for Q4 2021, and its period low was -$474.8 million during Q2 2021.
  • In the last 3 years, BeOne Medicines' EBITDA had a median value of -$120.3 million in 2024 and averaged -$137.6 million.
  • Its EBITDA has fluctuated over the past 5 years, first crashed by 731.76% in 2022, then spiked by 235.63% in 2025.
  • Over the past 5 years, BeOne Medicines' EBITDA (Quarterly) stood at $190.6 million in 2021, then crashed by 345.92% to -$468.6 million in 2022, then climbed by 18.10% to -$383.8 million in 2023, then spiked by 79.31% to -$79.4 million in 2024, then surged by 235.63% to $163.1 million in 2025.
  • Its EBITDA stands at $163.1 million for Q3 2025, versus $87.9 million for Q2 2025 and $11.1 million for Q1 2025.